Could a vaccine shield HIV-Exposed newborns? early trial launches

NCT ID NCT06613789

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: HIV Vaccine Trials Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial will test a new HIV vaccine in 22 infants who were exposed to HIV during birth but are not infected. The vaccine is designed to train the immune system to recognize and fight HIV. The main goal is to see if the vaccine is safe and whether it triggers an immune response. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 426c.Mod.Core-C4b vaccine with 3M-052-AF and alum adjuvants
What this could lead to: If successful, this could point toward a safe vaccine to protect HIV-exposed infants from infection.
What could go wrong: This is a very early Phase 1 trial with only 22 infants, so it is primarily checking safety, not effectiveness. The vaccine may not produce a strong immune response or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Soweto HVTN CRS

Soweto, Gauteng, 1862, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.